Actinium Pharmaceuticals, Inc.
Simbols: ATNM
AMEX
8.75
USDTirgus cena šodien
-5.2530
P/E koeficients
0.0000
PEG koeficients
260.61M
MRK Cap
- 0.00%
DIV ienesīgums
Actinium Pharmaceuticals, Inc. (ATNM) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 334.99 | 76.7 | 108.9 | 77.8 | ||||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.other-current-assets | 9.78 | 1.6 | 2 | 1.9 | ||||||||||||||||||
balance-sheet.row.total-current-assets | 344.77 | 78.3 | 110.9 | 79.7 | ||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 11.78 | 2.9 | 2.9 | 0.6 | ||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.long-term-investments | 1.25 | 0.3 | 0.3 | 0 | ||||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0 | -0.6 | ||||||||||||||||||
balance-sheet.row.total-non-current-assets | 13.02 | 3.2 | 3.3 | 0.6 | ||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-assets | 357.79 | 81.4 | 114.2 | 80.4 | ||||||||||||||||||
balance-sheet.row.account-payables | 32.25 | 8 | 10.1 | 5.5 | ||||||||||||||||||
balance-sheet.row.short-term-debt | 2.13 | 0.5 | 0.5 | 0.3 | ||||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.long-term-debt-total | 6.51 | 1.6 | 2.1 | 0 | ||||||||||||||||||
Deferred Revenue Non Current | 140 | 35 | 35 | 0 | ||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | -106.57 | - | - | - | ||||||||||||||||||
balance-sheet.row.other-current-liab | -104.46 | -35 | -35 | 0 | ||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 146.51 | 36.6 | 37.1 | 0 | ||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 7.55 | 1.6 | 2.6 | 0.3 | ||||||||||||||||||
balance-sheet.row.total-liab | 180.9 | 45.1 | 47.7 | 6.8 | ||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.common-stock | 0.11 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.retained-earnings | -1327.08 | -337.6 | -288.8 | -255.7 | ||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 1503.86 | 373.9 | 355.2 | 329.3 | ||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 176.9 | 36.4 | 66.5 | 73.5 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 357.79 | 81.4 | 114.2 | 80.4 | ||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-equity | 176.9 | 36.4 | 66.5 | 73.5 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 357.79 | - | - | - | ||||||||||||||||||
Total Investments | 1.25 | 0.3 | 0.3 | 0 | ||||||||||||||||||
balance-sheet.row.total-debt | 8.64 | 2.1 | 2.6 | 0.3 | ||||||||||||||||||
balance-sheet.row.net-debt | -326.35 | -74.6 | -106.3 | -77.5 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -46.45 | -48.8 | -33 | -24.8 | ||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0.82 | 0.8 | 0.7 | 0.5 | ||||||||||||||||||
cash-flows.row.deferred-income-tax | -3.47 | 2.2 | 0.4 | -1.5 | ||||||||||||||||||
cash-flows.row.stock-based-compensation | 4.23 | 3.8 | 2.8 | 1.7 | ||||||||||||||||||
cash-flows.row.change-in-working-capital | 1.77 | -3.1 | 38.2 | 1.7 | ||||||||||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.account-payables | 0.15 | -2.2 | 4.6 | 1.2 | ||||||||||||||||||
cash-flows.row.other-working-capital | 1.61 | -1 | 33.6 | 0.5 | ||||||||||||||||||
cash-flows.row.other-non-cash-items | 5.72 | -2.2 | -0.4 | 1.5 | ||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -39.63 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.09 | -0.2 | -0.4 | -0.1 | ||||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -0.09 | -0.2 | -0.4 | -0.1 | ||||||||||||||||||
cash-flows.row.debt-repayment | -0.01 | 0 | 0 | -0.1 | ||||||||||||||||||
cash-flows.row.common-stock-issued | 28.61 | 14.9 | 23.2 | 35.3 | ||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.other-financing-activites | 19.08 | 0.3 | 23.1 | 0 | ||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 28.87 | 14.9 | 23.1 | 35.2 | ||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.net-change-in-cash | -10.86 | -32.6 | 31.4 | 14.2 | ||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 335.61 | 76.7 | 109.6 | 78.2 | ||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 346.46 | 109.3 | 78.2 | 64 | ||||||||||||||||||
cash-flows.row.operating-cash-flow | -39.63 | -47.3 | 8.6 | -20.9 | ||||||||||||||||||
cash-flows.row.capital-expenditure | -0.09 | -0.2 | -0.4 | -0.1 | ||||||||||||||||||
cash-flows.row.free-cash-flow | -39.72 | -47.5 | 8.3 | -21 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0.08 | 0.1 | 1 | 1.1 | ||||||||||||||||||
income-statement-row.row.cost-of-revenue | 0.82 | 0.8 | 0.7 | 0.5 | ||||||||||||||||||
income-statement-row.row.gross-profit | -0.74 | -0.7 | 0.3 | 0.6 | ||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||
income-statement-row.row.research-development | 37.04 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-general-administrative | 12.56 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | -0.22 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | ||||||||||||||||||
income-statement-row.row.operating-expenses | 49.6 | 51.2 | 35.1 | 26.1 | ||||||||||||||||||
income-statement-row.row.cost-and-expenses | 50.01 | 52 | 35.1 | 26.1 | ||||||||||||||||||
income-statement-row.row.interest-income | 3.48 | 3.1 | 1.1 | 0.2 | ||||||||||||||||||
income-statement-row.row.interest-expense | 0.55 | 0 | -1.1 | 0 | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | -0.22 | - | - | - | ||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 3.48 | 3.1 | 1.1 | 0.2 | ||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | ||||||||||||||||||
income-statement-row.row.total-operating-expenses | 3.48 | 3.1 | 1.1 | 0.2 | ||||||||||||||||||
income-statement-row.row.interest-expense | 0.55 | 0 | -1.1 | 0 | ||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0.82 | 0.8 | 0.7 | 0.5 | ||||||||||||||||||
income-statement-row.row.ebitda-caps | -49.11 | - | - | - | ||||||||||||||||||
income-statement-row.row.operating-income | -49.93 | -51.9 | -34.1 | -25 | ||||||||||||||||||
income-statement-row.row.income-before-tax | -46.45 | -48.8 | -33 | -24.8 | ||||||||||||||||||
income-statement-row.row.income-tax-expense | 0.55 | 0 | -1.1 | -0.2 | ||||||||||||||||||
income-statement-row.row.net-income | -46.45 | -48.8 | -31.9 | -24.6 |
Biežāk uzdotie jautājumi
Kas ir Actinium Pharmaceuticals, Inc. (ATNM) kopējie aktīvi?
Actinium Pharmaceuticals, Inc. (ATNM) kopējie aktīvi ir 81445000.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir 81000.000.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir -9.173.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir -1.424.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir -573.469.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir -616.457.
Kāda ir Actinium Pharmaceuticals, Inc. (ATNM) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir -48818000.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 2113000.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 51211000.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 84057000.000.